Apolipoprotein and inflammatory biomarker changes following marked triglyceride reduction with the GalNAc-conjugated APOC3 siRNA RBD5044
RBD5044, a GalNAc-conjugated small interfering RNA (siRNA) targeting APOC3, demonstrated robust lipid-lowering efficacy in a Phase I clinical trial. It achieved a 70% reduction in plasma triglyceride (TG) levels, with over 50% reduction maintained at six months. Elevated apoC-III concentrations have previously be...